Effect and safety of immune checkpoint inhibitors in metastatic lung cancer: A retrospective study

TL;DR

This study examines the effectiveness and safety of immune checkpoint inhibitors in treating metastatic lung cancer.

Contribution

The study reports a 60% clinical benefit ratio in a small patient cohort.

Findings

A 60% clinical benefit ratio was observed in 30 patients treated with immune checkpoint inhibitors.

The study highlights limitations such as small sample size and patient heterogeneity.

Abstract

Cancer is a major global public health issue. Immune checkpoint inhibitors are increasingly used for managing advanced malignancies.
However, their effect is limited by immune-related adverse events. Hence, a retrospective, single-institutional study found a 60%
clinical benefit ratio among 30 patients receiving Immune checkpoint inhibitors therapy. Nonetheless, a small sample size, patient
heterogeneity and retrospective design require further validation for more conclusive results.